N/A N=63 Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Obesity · Metabolic Syndrome
Primary: In Vivo Adipose Cell Formation (Adipogenesis) — -0.3; 1.8; -1.2; 2.1 percent
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Changes in Ectopic Fat Following Surgically Induced Weight Loss
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Triglyceride (Fat) Content — 6.44; 2.08 percent
Phase 2 N=22 Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls
Obesity
Primary: Change in Visceral and Subcutaneous Abdominal Adipose Tissue Over 6 Months — 57; 799; -111; 3634 mm^2 — p=0.70
N/A N=81 Effects of Different Surgical Methods to Treat Obesity
Obesity · Type 2 Diabetes · Insulin Sensitivity
Primary: Insulin Sensitivity at 2 Years — 6.7; 6.6 glucose/kg body weight/min
Phase 2 N=60 Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Abdominal Obesity · Growth Hormone Deficiency
Primary: Change in Visceral Adipose Tissue Volume — -16; 19 cm2
N/A N=60 Non-Invasive Reduction of Abdominal Fat
Fat Reduction
Primary: Proportion of Pre-treatment Images Correctly Identified — 128 photos — p=<0.001
Phase 3 N=79 Prevention of Obesity in Women Via Estradiol Regulation
Obesity
Primary: Resting Energy Expenditure (REE) — -37.8; -87.2; 14.6; -19.3 kcal/d — p=<0.05
N/A N=12 Soy as an Innovative Dietary Component in Abdominal Obesity Management Amongst Peri- and Early Menopausal Women
Central Obesity
Primary: Body Fat (kg) — 40.96; 40.12; 2.94; 4.26 kg
N/A N=27 Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation
Metabolic Syndrome X · Prediabetic State
Primary: Insulin Sensitivity — 1.48; 1.73; 1.89; 2.93 mg*kg^-1*min^-1
N/A N=101 Role of Pancreatic Triglyceride Content in Beta-cell Function
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Fat — 1.87; 6.57; 3.61; 5.85 percent
N/A N=39 Sonographic Evaluation of Visceral Fat After Bariatric Surgery
Morbid Obesity
Primary: Decrease in the Visceral Fat Layer Measured by Ultrasound a Day Before and a Year After Surgery. — 3.6; 7.1; 5.6 visceral fat reduction in centimeters
N/A N=82 Fructose Consumption and Metabolic Dysregulation
Central Obesity · Hypertriglyceridemia
Primary: TG Plasma AUC — 1130; 1220 mmol/l*min — p=0.005
Phase 4 N=32 Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
Type 2 Diabetes · Hypertension
Primary: Changes in Systolic Blood Pressure During Initial Intralipid Infusion — 23; 13 mmHg
N/A N=12 The Effects of Alcohol Consumption on Central Adiposity
Alcohol Drinking · Weight Loss · Adiposity
Primary: Change in Central (Abdominal) Adiposity — -0.250; -0.071 kg — p=<0.231
N/A N=90 Effects of CPAP on Visceral Fat Thickness
Obstructive Sleep Apnea
Primary: Mesenteric Fat Thickness — 0.96; 0.94 cm
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
N/A N=9 Toward an Automated Method of Abdominal Fat Segmentation of MR Images
Obesity
Primary: Visceral Fat Volume With Automated Analysis — 994 cubic centimeters
N/A N=46 Eplerenone in HIV Associated Abdominal Fat Accumulation
HIV
Primary: Insulin Stimulated Glucose Uptake — 7.70; 8.58 mg/min per μIU/ml — p=0.71
N/A N=29 Clinical Effectiveness of Body Fat Distribution Imaging in Real-World Practice: The BODY-REAL Study
Overweight and Obesity · PreDiabetes · Type 2 Diabetes
Primary: Change in BMI — 0.43; 0; 4.4; 0 kg/m2 — p=0.2
N/A N=45 Aerobic Training and Non-Exercise Physical Activity
Central Obesity · Obesity
Primary: Change in Waist Circumference — -1.3; -1.9; -4.1 cm — p=0.074
Phase 4 N=20 Metabolic Abnormalities in HIV-infected Persons
Lipodystrophy · HIV Infection
Primary: Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent — -0.25; -0.96 mg/kg lean body mass/min
Phase 4 N=38 Liraglutide Effects on Epicardial Fat Inflammatory Genes
Type2 Diabetes · Coronary Artery Disease
Primary: EAT Inflammation — 0.70; 1.4; 0.39; 0.25 ct (cycle threshold)
N/A N=40 Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Acromegaly
Primary: Change in Liver Fat — 0.03 Lipid/water ratio
N/A N=18 The Effects of Chiropractic in a Population With High Central Adiposity
Abdominal Obesity
Primary: Proportion of Potential Participants Who Are Eligible. — 0.95 Proportion
N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL
N/A N=137 Beige Fat, Energy, and the Natriuretic Peptide System
Obesity
Primary: Adipose Tissue Gene Expression of UCP1 (Uncoupling Protein 1)- Differences by Obesity Status — 7.79; 24.33 fold change — p=<0.01
N/A N=93 Exercise Regulation of Human Adipose Tissue
Healthy · Obese · Diabetes Mellitus, Type 2
Primary: Changes in Human Adipose Tissue Characteristics Following Exercise Training — 25.45; 34.12; 38.06; 27.05 body fat %
Phase 3 N=59 Rosuvastatin in Visceral Adiposity
Abdominal Obesity
Primary: Change in Visceral Adipose Tissue Area Measured by Computed Tomography. — -1.5; 2.8 cm2
Phase 4 N=24 Effect of Exenatide on Liver and Heart Fat and Inflammation
Type 2 Diabetes Mellitus
Primary: Myocardial Fat Content — 1.7; 1.1 percentage of myocardium content
N/A N=51 Preventing Excessive Weight Gain and Maternal and Infant Fat Accretion
Gestational Weight Gain · Maternal Fat Accretion · Infant Fat Accretion
Primary: Maternal Weight Changes — 70.20; 66.47; 80.12; 75.80 kg